Loading...
OTCM
CSCIF
Market cap6mUSD
Dec 05, Last price  
2.09USD
1D
1.46%
1Q
-12.92%
Name

Aeterna Zentaris Inc

Chart & Performance

D1W1MN
OTCM:CSCIF chart
P/E
—
P/S
0.46
EPS
—
Div Yield, %
—
Shrs. gr., 5y
29.83%
Rev. gr., 5y
91.73%
Revenues
14m
+200.91%
247,389,00041,392,00042,068,00038,478,00063,237,00027,703,00036,053,00033,665,0006,175,00011,000545,000911,000923,00026,881,000532,0003,652,0005,260,0005,640,0004,580,48713,783,134
Net income
-15m
L-9.18%
10,571,00033,390,000-32,296,000-59,817,000-24,724,000-23,218,000-27,067,000-20,412,0006,815,000-16,564,000-50,143,000-24,959,000-16,796,0004,187,000-6,042,000-5,118,000-8,368,000-37,669,000-16,855,544-15,309,000
CFO
-15m
L-16.43%
12,934,0007,957,000-25,530,000-1,272,000-24,138,000-31,120,000-26,243,000-30,815,000-19,984,000-31,082,000-33,844,000-29,010,000-22,913,0006,825,000-10,725,000-4,129,000-8,581,000-13,680,000-17,431,923-14,568,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
URL
https://www.zentaris.com/
IPO date
Dec 19, 1995
Employees
12
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT